May 2021 Publications
- The subunit vaccine H65+ CAF01 increased the BCG-protection against Mycobacterium bovis infection in a mouse model of bovine tuberculosis. Blanco FC, García EA, Aagaard C, Bigi F. Res Vet Sci. 2021 May. doi: 10.1016/j.rvsc.2021.04.014. Epub 2021 Apr 14.
- HLA-DR-Positive NK Cells Expand in Response to Mycobacterium Tuberculosis Antigens and Mediate Mycobacteria-Induced T Cell Activation. Kust SA, Streltsova MA, Panteleev AV, Karpina NL, Lyadova IV, Sapozhnikov AM, Kovalenko EI. Front Immunol. 2021 May 3. doi: 10.3389/fimmu.2021.662128.
- Exaggerated IL-17A activity in human in vivo recall responses discriminates active tuberculosis from latent infection and cured disease. Pollara G, Turner CT, Rosenheim J, Chandran A, Bell LC, Khan A, Patel A, Peralta LF, Folino A, Akarca A, Venturini C. Sci Transl Med. 2021 May 5. doi: 10.1126/scitranslmed.abg7673.
- BCG Cell Wall Skeleton As a Vaccine Adjuvant Protects Both Infant and Old-Aged Mice from Influenza Virus Infection. Kim KH, Lee YT, Park Y, Ko EJ, Jung YJ, Kim YJ, Jo EK, Kang SM. Biomedicines. 2021 May 5. doi: 10.3390/biomedicines9050516.
- IL-1R1-Dependent Signals Improve Control of Cytosolic Virulent Mycobacteria In Vivo. van der Niet S, van Zon M, de Punder K, Grootemaat A, Rutten S, Moorlag SJ, Houben D, van der Sar AM, Bitter W, Brosch R, Pando RH. Msphere. 2021 May 5. doi: 10.1128/mSphere.00153-21.
- Robust IgM responses following vaccination are associated with prevention of Mycobacterium tuberculosis infection in macaques. Irvine EB, O’Neil A, Darrah PA, Shin S, Choudhary A, Li W, Honnen W, Mehra S, Kaushal D, Gideon HP, Flynn JL. bioRxiv. 2021 May 06. doi: 10.1101/2021.05.06.442979.
- A century of BCG: Impact on tuberculosis control and beyond. Ahmed A, Rakshit S, Adiga V, Dias M, Dwarkanath P, D’Souza G, Vyakarnam A. Immunol Rev. 2021 May 06. doi: 10.1111/imr.12968.
- Monkeying around with MAIT Cells: Studying the Role of MAIT Cells in SIV and Mtb Co-Infection. Moriarty RV, Ellis AL, O’Connor SL. Viruses. 2021 May 8. doi: 10.3390/v13050863.
- Balance between Protection and Pathogenic Response to Aerosol Challenge with Mycobacterium tuberculosis (Mtb) in Mice Vaccinated with TriFu64, a Fusion Consisting of Three Mtb Antigens. Sulman S, Savidge BO, Alqaseer K, Das MK, Nezam Abadi N, Pearl JE, Turapov O, Mukamolova, GV, Akhtar MW, Cooper AM. Vaccines (Basel). 2021 May 18. doi: 10.3390/vaccines9050519.
- Discovering mycobacterial lectins as potential drug targets and vaccine candidates for tuberculosis treatment: a theoretical approach. Sundar S, Thangamani L, Piramanayagam S, Natarajan J. J Proteins Proteom. 2021 May 18. doi: 10.1007/s42485-021-00065-y.
- Mining the Mycobacterium tuberculosis proteome for identification of potential T-cell epitope based vaccine candidates. Madan R, Pandit K, Bhati L, Kumar H, Kumari N, Singh S. Microb Pathog. 2021 May 24. doi: 10.1016/j.micpath.2021.104996.
- Sterilizing immunity: New opportunities for rational TB vaccine design. Sher A, Flynn JL. J Exp Med. 2021 jul 5. doi: 10.1084/jem.20210454. Epub 2021 May 26.
- Will there be a RNA vaccine for TB? Fan XY, Lowrie DB. Emerg Microbes Infect. 2021 May 26. doi: 10.1080/22221751.2021.1935328.
- Comparing cytokine production and clinical response following vaccination with BCG Moreau and BCG Russia strains in a Brazilian infant population. Bitencourt J, Sarno A, Oliveira C, de Souza RA, Lima CC, Takenami I, Pereira SM, Arruda S. Vaccine. 2021 May 27. doi: 10.1016/j.vaccine.2021.04.028. Epub 2021 May 5.